In an attempt to enhance the fibrinolytic activity of endothelial cells (EC), a retroviral vector containing the human tissue-type plasminogen activator (t-PA) cDNA was constructed. Sheep EC were stably transduced with the vector, resulting in a 30-fold increase in t-PA activity over that detected in EC transduced with a control vector. Southern and Northern analyses confirmed the presence of both the vector sequence and the appropriate mRNA transcripts. Secretion of high levels of recombinant human t-PA continued in vitro for the duration of the experiments, up to 11 weeks after transduction, although the rate of t-PA secretion decreased in some of the EC lines. Zymographic analysis of conditioned medium from t-PA-transduced EC showed the HE VASCULAR ENDOTHELIUM is an active partic-T ipant in the regulation of coagulation and thrombolysis. Endothelial cells (EC) synthesize procoagulant, anticoagulant, and thrombolytic molecules including heparan sulfate,' tissue-type plasminogen activator (t-PA),' type 1 plasminogen activator inhibitor (PAI-l),3 protein S,4 thrombospondin? and von Willebrand factor? In addition, EC possess binding sites for plasminogen,' thrombin: and factors IX and X,.9,'0 Because achievement of a balance between coagulation and thrombolysis appears to be dependent on the interplay of these EC functions, enhancement of the thrombolytic activity of EC might offer an approach to the treatment of prevention of intravascular thrombosis.
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t-PA, synthesized largely by the endothelium, is a major participant in the regulation of intravascular coagulation.'' In recognition of this role, significant efforts have been devoted to the understanding of EC synthesis and secretion of t-PA'* in the hope that through this understanding methods might be found to enhance EC secretion of t-PA as a means of preventing and treating intravascular thrombosis. In vivo, t-PA release is reportedly increased by exercise, venous occlusion, mental stress, endotoxin, epinephrine, nicotinic acid, desmopressin acetate, and ethanol.''.'' In vitro, treatment of EC with thrombin, histamine, and sulfonylureas results in increased t-PA secretion.'"" However, none of these agents represents a reasonable therapeutic agent for the prevention or treatment of acute or subacute intravascular thrombosis. Intravenous administration of recombinant t-PA has emerged as the only currently used means of increasing in vivo t-PA levels."
Gene transfer te~hnolog$'-'~ has opened a new approach to the modification and enhancement of cellular function, and might be used to increase the rate of t-PAsecretion and the fibrinolytic activity of EC. An example of this approach is the use of retroviral vector-mediated gene transfer to affect the production of adenosine deaminase (ADA) in ADA-deficient cells for the potential therapy of patients suffering from ADA defi~iency.'~ In this gene transfer system high levels of protein production are ensured through the construction of retroviral-based vectors in which the ADA gene is spliced to a highly active promoter sequence. The cellular ADA activity that results from this presence of two new molecular species with plasminogen activator activity that could be specifically immunoprecipitated with a monoclonal antihuman t-PA antibody. The relative molecular masses of these species (60 to 80 and 110 Kd) suggest that they represent recombinant human t-PA both free and bound to sheep plasminogen activator inhibitor 1 (PAI-1). Consistent with this interpretation, the 110-Kd species could be specifically immunoprecipitated with antiserum to PAI-1. These studies demonstrate that retroviral vector-mediated gene transfer may be used to increase total EC fibrinolytic activity. This is a US government work. There are no restrictions on its use.
strategy of overexpression can actually exceed normal
We constructed a retroviral vector containing the human t-PA gene under the control of the SV-40 early promoter and used it to transduce sheep EC, resulting in very high level secretion of immunoreactive t-PA.= Measurement of immunoreactive protein is an important first step. However, because of the complexity of the EC fibrinolytic system, and particularly because of the ability of EC to produce a specific t-PA inhibitor (PAI-l), it is necessary to examine the net effect of overexpression of t-PA on the fibrinolytic activity of the transduced cells. In the present study we examine the effect of retroviral vector-mediated overproduction of human t-PA on the fibrinolytic activity of sheep EC, and examine the interactions of the recombinant t-PA molecule with endogenous sheep plasminogen activators and inhibitors. In addition, we explore the long-term in vitro expression of the inserted t-PA gene, and document the integration and expression of the gene on a molecular level.
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DICHEK ET AL studies: one femoral vein, two jugular veins, and three common carotid arteries. EC were harvested and their identity established as previously described.z Culture conditions were also as previously reported, except that for higher passages of the cells it became necessary to add heparin (100 bg/mL) (Sigma Chemical Co, St Louis, MO) and Endothelial Cell Growth Supplement (25 pg/mL) (Collaborative Research, Bedford, MA) to the medium to ensure continued cell proliferation.
We described previously26 the construction of the t-PA containing retroviral vector B2NSt, the PA-317" amphotropic (ie, able to transduce nonrodent cells) retroviral vector producer cells, and the transduction of sheep EC with the B2NSt vector and the P-galactosidase containing BAG vector." After at least 4 weeks of G418 selection, cells from three of the transductions (two jugular veins and one carotid artery) were taken out of G418 selection to determine the effect of the removal of selective pressure on continued expression of the t-PA gene.
DNA was harvested from confluent monolayers of cells, essentially as de~cribed;~ digested with either Xba I (B2NSt transduced cells) or BamHI (BAG transduced cells), run on 0.8% agarose gels, and transferred to nylon membranes (Nytran; Schleicher and Schuell, Inc, Keene, NH). The blots were UV cross-linked and then hybridized overnight at 65°C to either a 1.4-kb Sac I fragment of the t-PA cDNA (the "t-PA probe") or a 2.5-kb Au I1 fragment of plasmid pCH-llOW (Pharmacia LKB Biotechnology, Piscataway, NJ), which contains only sequences internal to the lacZ gene (the "IacZ probe"). Washing of blots was performed at 65°C in 0.2X standard saline citrate, 0.1% sodium dodecyl sulfate (SDS). Blots were autoradiographed at -70°C using Kodak XAR film (Eastman Kodak, Rochester, NY). All cDNA probes used to detect sequences present in Southern and Northern blots were labeled by the random primer method" using "P-labeled deoxynucleotides.
Total cellular RNA was extracted and purified using guanidinium isothiocyanate and cesium chloride centrifugati0n.j' Ten micrograms of each sample was electrophoresed through 1.2% agarose gels and blotted onto nylon nitrocellulose membranes (Micron Separations, Inc, Westboro, MA), which were then vacuum dried and hybridized to either the aforementioned t-PA probe, the lacZ probe, or a 1.5-kb EcoRI fragment of the plasmid pB2N, containing only sequences internal to the neomycin resistance gene (the "Ne0 probe"). Hybridization, washing, and autoradiography were performed as described for Southern blots.
Quantitation of human t-PA antigen and total protein in conditioned medium (CM). The amount of human t-PA antigen was determined using an enzyme-linked immunosorbent assay (ELISA) kit, "Imubind-5 t-PA' (American Diagnostica, New York, NY), which is capable of detecting 1.5 ng/mL of t-PA. Supernatant to be assayed was collected 48 hours after the addition of 2 mL of medium to confluent monolayers of cells in 35-mm tissue culture wells. Collected medium was centrifuged at 15,OOOg for 15 minutes to remove cellular debris, made 0.01% with Tween 80, and frozen at -70°C until assayed. Total protein was determined with the Bio-Rad dye reagent (Bio-Rad, Richmond, CA), using bovine y-globulin as a standard.
For quantitation of t-PA activity in the CM of the transduced cells, confluent monolayers were washed twice, then incubated in 1.5 mL of serum-free medium (M-199 with added glutamine). After 24 hours, the medium was collected and acidified immediately with an equal amount of 1.0 mol/L sodium acetate buffer, pH 3.9, to prevent further reaction between free t-PA and any endogenous sheep PAL3* The samples Retroviral vector-mediated gene transfer.
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were then centrifuged at 15,000g for 15 minutes at 4°C and frozen at -70°C until assayed. Samples were assayed immediately on thawing using a kit, "Spectrolyse/fibrin t-PAPAI" (American Diagnostica), capable of detecting 0.0025 IU/mL of t-PA. In this assay t-PA specificity is achieved by incubation of samples with desAA fibrinogen along with glu-plasminogen and the chromogenic substrate D-butyl-cyclohexyltyrosyl-lysine-paranitroaniline. 33 We adapted the assay for the measurement of t-PA activity in tissue culture supernatants by diluting the activity standards with acidified serum-free medium instead of acidified PAI-depleted plasma.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and zymographic analysis. Electrophoresis and zymographic analysis were performed as described by Roche et aIj4 with the following modifications: 4.8 mL of 4.5% stacking gel and 10.3 mL of 11% separating gel containing 1.6% wt/vol bovine casein (nonfat dry milk) and 2.2 p,Lg/mL human glu-plasminogen (American Diagnostics) were used. We chose plasminogen casein zymography over fibrin overlays for the superior resolution that zymography offed4 because we anticipated that this would be needed in a complex mixture of plasminogen activators. Samples for SDS-PAGE and zymography were collected in serum-free medium and processed and frozen as described for samples used for the t-PA antigen assay. For immunoprecipitation of recombinant human t-PA, CM was incubated with a Sepharose-conjugated murine monoclonal antibody (MoAb) to human t-PA, "PAM-2'' (American Diagnostics), for 2 hours at room temperature with gentle rotation, followed by centrifugation at 15,OoOg for 30 seconds to remove the Sepharose. Control samples were incubated with phosphatebuffered saline (PBS) or Sepharose instead of PAM-2. For specific removal of molecular species containing sheep PAI-1, CM was immunoprecipitated with Protein A Sepharose (Pharmacia) affinity bound to either a rabbit polyclonal antiserum to rat PAI-1 (American Diagnostica) or to normal rabbit serum as a control, as described above. Before electrophoresis certain samples were incubated with 1% SDS at 37°C for 30 minutes to recover latent plasminogen activator activity.* All samples were diluted with an equal volume of a nonreducing loading buffer consisting of 0.125 mom Tris-HCI, pH 6.8, 40% glycerol, 3% SDS, and 0.1% Bromphenol Blue before being subjected to SDS-PAGE. Samples were run at 20 mA per gel through the stacking gel and at 30 mA per gel through the separating gel. After electrophoresis, gels were rinsed in distilled water, washed twice in 500 mL of 2.5% Triton X-100 (Research Products International, Mount Prospect, IL) for 30 minutes each, and incubated overnight in 500 mL of 0.1 mol/L glycine, pH 8.0. Gels were then stained with 0.1% Amido Black in 10% acetic acid and 20% methanol, and destained in 10% acetic acid, 20% methanol. Gels were photographed and the negatives were reversed before printing, so that zones of lysis appear as dark bands on the final prints. Size markers were prestained P-galactosidase (116 Kd) and phosphorylase B (96 Kd) (Diversified Biotech, Newton Centre, MA). Human t-PA (66 Kd), high molecular weight urokinase (54 Kd), and low molecular weight urokinase (33 Kd) (American Diagnostica) served as both size markers and zymography positive controls.
RESULTS
To confirm that the B2NSt-transduced EC contained the appropriate DNA sequence, we used a t-PA cDNA fragment t o probe Southern observed. Comparison of the intensity of the 4.9-kb band to that produced by hybridization to a known amount of plasmid DNA indicated that approximately one copy per cell had been introduced (Fig 2, and data not shown) . Hybridization of the lacZ probe to Southern blots showed the presence of the expected 3-kb BamHI fragmentZR in DNA from BAG-transduced cells (data not shown). No hybridization of the lacZ probe to Southern blots of DNA from B2NSt-transduced cells could be detected.
Hybridization of the t-PA probe to Northern blots confirmed the presence of both the fulllength (5.5 kb) and the internally promoted (2.9 kb) transcripts in both the target EC and the PA-317 producer line (Figs 1 and 3) . The full-length transcript, initiated from the viral long terminal repeat (LTR), was consistently more abundant than the internally promoted transcript, initiated from the SV-40 promoter. Hybridizations performed with the Neo probe showed, as expected, the 5.5-kb transcript but not the 2.9-kb transcript in the B2NSt-transduced cells (data not shown). In addition, the Neo probe detected the predicted 3-kb internally promoted neomycin phosphotransferase transcriptZR in BAG-transduced cells only (data not shown).
Transduction of EC from each of the vessels with the B2NSt vector was followed by secretion of high concentrations of human t-PA (Fig4, and data not shown). Cells transduced with the BAG Northem analysis.
Secretion of immunoreactive human t-PA. vector never produced detectable immunoreactive human
To determine whether the production of recombinant t-PA by the transduced cells was stable over time and in the absence of continued G418 selection, cells from four of the vessels (two carotid arteries and two jugular veins) were maintained in culture for up to 11 weeks after transduction. Human t-PA levels were measured regularly, always at confluence. For three of these vessels, half of the B2NSt-transduced cells were removed from G418 selection for 30 days (Fig 4, and data not shown) . All B2NSt-transduced cells continued to secrete human t-PA. The concentration of immunoreactive t-PA in the CM of the confluent carotid artery cells remained stable for several weeks after transduction (Fig 4 A, and data not shown) . During this time cell density at confluence increased from 3 to 4 x lo4 cells/cm2 to 5 to 6 x lo4 cells/cm2 (this increase coincided with the addition of heparin and endothelial cell growth supplement to the medium). As a result of this increase in cell density, the amount of t-PA secretion per cell actually decreased, although the total t-PA secretion per square centimeter of EC surface remained the same. In contrast, measurement of t-PA levels in the CM from both lines of jugular vein EC showed a decrease of approximately 50% about 5 to 6 weeks after transduction, followed by a plateau (Fig 4B, and data not shown). An increase in cell density similar to that found in the carotid artery cells also occurred in later passages of the jugular vein cells, again temporally associated with the addition of heparin and endothelial cell growth supplement. In all three cases persistence of t-PA t-PA. secretion was unrelated to the continued presence of G418 in the medium (Fig 4, and data not shown) , and there was no significant difference in cell density between cells grown with and without G418.
We measured t-PA activity in the supernatants of B2NSt-and BAG-transduced carotid artery EC (Table 1) . Supernatant from the BAGtransduced cells contained a low but detectable amount of activity in this assay, in which the presence of desAA fibrin provides only relative specificity for t-PA over urokinaselike plasminogen activators. A 30-fold increase in t-PA activity was measured in the supernatant of the B2NSt-transduced cells. In a separate experiment, in which desAA fibrin was omitted from the assay, no increase in t-PA activity could be detected in B2NSt versus control transduced cells (data not shown). In addition to t-PA activity, human t-PA antigen levels were determined, allowing the calculation of a ratio of increase in t-PA activity per mass of recombinant t-PA expressed. The t-PA activity in the supernatant increased by approximately 1.3 x lo4 IU/mg of recombinant t-PA expressed. At earlier stages (days 21 through 59 after transduction), higher levels of t-PA activity (ranging up to 2.9 and 0.09 IU/mL for the B2NSt-and BAG-transduced cells, respectively) were detected. The
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relative increase in t-PA activity of the B2NSt-transduced cells also varied (between 20-and 80-fold), as did the ratio of t-PA activity to mass of recombinant t-PA (up to 8 X lo4 IU/mg). Although these earlier samples were obtained using slightly different procedures and were not obtained from triplicate wells (therefore they are not included in Table l), they suggest that higher levels of t-PA activity might be detected at earlier time points. Harvests of the indicated cells were maintained in culture for the time indicated on the abscissa. The dates of transduction and initiation of 6418 selection are indicated by "T" and "S," respectively. Collection of CM for the t-PA antigen assay was performed regularly, always according t o the same protocol: cells were grown in 35-mm wells and fed with 2 mL of medium on alternate days. On the day on which the cells reached confluence, their medium was discarded and 2 mL of fresh medium was added. This new medium was harvested 48 hours later. In this manner all collections were done for the same time period over the same total surface area of confluent cells. On day 45 for the carotid artery cells and day 55 for the jugular vein cells, duplicate cultures were set up by passaging an aliquot of t-PA-transduced cells into G418 free medium. These G418 free cultures were maintained in parallel and treated in an otherwise identical manner t o G418 containing cultures of the same line of cells. Zymographic analysis of CM. Zymography using casein plasminogen gels showed plasminogen activator activity in four different molecular weight species in the supernatant of BAG-transduced cells (Fig 5, lanes 2 and 4) (Fig 5, lane 3) . (3) SDS pretreatment of the B2NSt supernatants resulted in an increase in the plasminogen activator activity in both the 110-Kd and 60-to 80-Kd bands, and often in a better resolution of the 85-and 90-Kd bands (Fig 5, lane 5) . Substitution of water for plasminogen in the gels resulted in elimination of all of the lysis zones. Serum-free medium also produced no lysis zones when run into the casein plasminogen gels (data not shown).
To determine which of the plasminogen activator species contained recombinant human t-PA, CM was immunoprecipitated with Sepharose conjugated with a murine MoAb to human t-PA before SDS-PAGE Zymography. Immunoprecipitation of CM of B2NSt-transduced cells resulted in the selective removal of the 110-Kd and 60-to 80-Kd plasminogen activators (Fig 6A, lane 1 v 2 and lane 3 v 4) . Nonspecific absorption by the Sepharose-conjugated anti- 4) and BAG-transduced cells (lanes 2 and 5) . as well as a solution of 2 ng of human t-PA in 50 pL of 70 pg/mL bovine serum albumin (lanes 3 and 6), were immunoprecipitated with either antiserum t o PAL1 (lanes 1 through 3) or normal rabbit serum (lanes 4 through 6). as described in Materials and Methods. Fiftv microliters of each of the absorbed supernatants was incubated with 1% SDS at 37°C for 30 minutes and run into a casein plasminogen gel. The zymography standard lane (STD) contains 1 ng of t-PA, 75 ng of high molecular weight urokinase, and 25 ng of low molecular weight urokinase.
body resulted in comparatively small decreases in the intensity of the sheep plasminogen activator bands. On some of the gels, the 85-Kd band could not be visualized after immunoprecipitation (Fig 6A, lane 4) . However, loading of larger amounts of sample showed the presence of this band without restoration of either the 110-Kd or 60-to 80-Kd bands (data not shown). Medium from BAGtransduced cells exhibited the same zymographic pattern with or without immunoprecipitation with antihuman t-PA (data not shown). Immunoprecipitation of CM of B2NSt-and BAG-transduced cells with rabbit anti-PAI-1 antiserum resulted in the removal of the 85, 90-and 110-Kd plasminogen activator-containing species (Fig 6B, lanes 1  and 2) . These three species were not precipitated with normal rabbit serum (Fig 6B, lanes 4 and 5) . In addition, purified human t-PA was not precipitated by either of the antisera (Fig 6B, lanes 3 and 6) .
DISCUSSION
The results of this study demonstrate that retroviral vector-mediated gene transfer can be used to enhance the fibrinolytic activity of EC. More specifically, a cDNA encoding a human plasminogen activator can be inserted into the genome of sheep EC, and this DNA segment is transcribed and translated into a functional protein that is secreted by the cells in an active form and participates in complex interactions with endogenous sheep plasminogen activators and inhibitors. Sheep EC transduced with the human t-PA gene have an enhanced capability to activate plasminogen and therefore promote the lysis of thrombi that form on or near their surfaces.
The rate of production of t-PA by B2NSt-transduced sheep EC is higher than any previously reported by cultured human endothelium? and the levels of recombinant t-PA achieved in vitro are clearly sufficient to activate plasminogen (see Fig 5 and Table 1 ). This result is in agreement with previous work showing that EC t-PA production can be regulated at the mRNA Ie~el>'~~' Our Northern blots show that in both PA-317 cells and sheep EC the steady-state concentration of full-length transcripts (initiated from the viral LTR) is greater than that of the internal transcripts (initiated from the SV-40 promoter) (Fig 3) . While the activity of a promoter in a viral vector is dependent on both the inherent activity of the promoter in the target cell and the presence of interference from nearby promoters,'8 the low level of SV-40-promoted transcripts compared with LTR-promoted transcripts indicates that it may be possible to further increase EC t-PA production through the use of promoter sequences that are more highly active in these target cells. Of note, when the B2NSt vector is expressed in human umbilical vein endothelial cells the full length and internally promoted transcripts are of approximately equal abundance (data not shown). Alternatively, t-PA mRNA levels and consequent protein production might be increased through the use of 3' untranslated sequences, which increase mRNA stability.'9 However, as levels of t-PA transcripts increase it may be possible that the rate-limiting step in EC t-PA production will become translation, posttranslational processing, or secretion. Palmer et ala showed that production of factor IX by retroviral vector-transduced fibroblasts is limited by the rate of y-carboxylation. the analysis of the pathways of and limitations to EC t-PA production.
Measurement of t-PA levels in the CM of the transduced cells during several weeks of in vitro culture showed the persistence of high-level t-PA secretion. However, during this time the rate of t-PA secretion per cell decreased in all three cell lines and the total rate of t-PA secretion per unit of endothelialized surface decreased in the two cultures of jugular vein EC. Stability of expression from transgenes inserted via retroviral-based vectors is incompletely ~nderstood.'~ In a recent study, Xu et aI4l reported that both genetic (eg, deletion) and epigenetic factors can contribute to a loss or decrease of transgene expression. Our data do not allow a clear determination of the etiology of the decrease in t-PA production. Further quantitative studies of transgene copy number, transcription rate, mRNA stability, and translation as well as secretion rates are required to define the exact mechanism(s) involved. Nevertheless, the secretion of recombinant t-PA continued at significant levels for several weeks after transduction and in the absence of continued selection in G418. These results suggest that long-term in vivo expression may be possible.
Transduction of sheep cells with the human t-PA gene resulted in an increase in total t-PA activity in the culture supernatants. At the time points represented in Table 1 , the increase was approximately 13,000 IU/mg of recombinant t-PA expressed. Purified recombinant human t-PA produced through the expression of the human cDNA in Chinese hamster ovary cells has a specific activity of 580,000 IU/mg.42 The large discrepancy between the specific activity of purified recombinant human t-PA and the activity-tomass ratio that we calculated is most likely due to the fact that we did not measure the activity of a purified protein.
The ELISA detects both free t-PA and t-PA bound to PAI with the same efficiency.43 It is probable that most of the t-PA secreted into the supernatant is eventually bound to PAI. Similarly, Wojta et al,35 also using an ELISA and an activity assay, measured t-PA antigen but no t-PA activity in the supernatant of cultured human umbilical vein and omental microvascular EC, apparently due to complete binding of t-PA by PAI-1. The recent report of a mutant human t-PA that retains catalytic activity yet binds only weakly to human PAI" offers a means to determine more precisely the contribution of t-PA-PA1 interactions to our results. The introduction of this molecule into EC should lead to an even greater increase in fibrinolytic activity.
A major consideration in the introduction of a new plasminogen activator gene into EC is the definition of the interactions of the gene product with endogenous plasminogen activators and inhibitors. Casein plasminogen zymography and immunoprecipitation analysis performed on CM show the existence of the following molecular species and interactions: (1) Control (BAG)-transduced sheep EC secrete two plasminogen activators (40 and 45 Kd) that are also detected as complexes with endogenous PA1 (85 and 90 Kd). These data predict the existence of a sheep PA1 molecule with a molecular weight of approximately 45 Kd, very close to the 45-and 50-Kd molecular masses of the human and bovine PAI m01ecules."~~~ Identification of the 85-and 90-Kd bands as PAI-containing complexes is supported by the fact that they can be specifically immunoprecipitated with anti-PA1 antiserum (Fig 6B, lanes 1 and  2) . (2) Transduction of sheep EC with the human t-PA cDNA results in the accumulation of human t-PA in the culture supernatant in two forms: free (60 to 80 Kd) and complexed with sheep PAI (110 Kd), again consistent with the existence of a sheep PA1 molecule of approximately 45 Kd. The 60-to 80-Kd band is broader than expected for human t-PA. Nevertheless, the entire band is enzymatically active and can be precipitated by an MoAb to human t-PA (Fig 6A) . The presence, in CM, of a broad rather than sharp band representing human t-PA has been reported by and may represent either heterogeneity of glycosylation or dissociation of free t-PA from t-PA-PA1 complex during the electrophoresis run. The identity of the 110-Kd band as a human t-PA sheep PAI complex, while not unequivocal, is strongly supported by the fact that it can be specifically precipitated with an antiserum to PAI-1 that does not cross-react with human t-PA (Fig 6B) . In addition, 1% SDS pretreatment of the CM of B2NSt-transduced cells, a procedure that is known to cause the recovery of plasminogen activator activity in t-PA-PA1 complexes,2 produced large increases in both the 110-Kd and 60-to 80-Kd casein lysis zones (Fig 5, lane 3 v lane 5) . This finding suggests that the recombinant t-PA molecule is associated with sheep PAI, and that this interaction is not completely stable to the SDS pretreatment. (3) Transduction of sheep EC with the human t-PA cDNA results in increased total activity of endogenous sheep plasminogen activators. Without specific assays to detect the masses of the various sheep plasminogen activator species we cannot determine whether the increased activity was accompanied by an increase in the total amount of each of the activators. Nevertheless, the finding of increased activity on the casein plasminogen gels was both consistent and unanticipated. It is possible that the human t-PA protein, by competing for sheep PA1 as a suicide substrate, allows the preservation and therefore the detection of increased endogenous sheep plasminogen activator activity. This hypothesis is consistent with previous data showing that addition of excess t-PA to EC cultures results in the trapping of PA1 in a t-PA-PA1 complex? and suggests that the use of competitive inhibitors of the plasminogen activator-PA1 interaction may be an alternative method to increase endogenous EC fibrinolytic activity.
Given that the fibrinolytic potential of EC may be enhanced, of what use is this technology to the treatment or prevention of disease? The association between thrombotic disease and abnormalities of either t-PA or PAI-1 is well If the balance between plasminogen activation and inhibition could be shifted in favor of activation, specifically on a local level, it might be possible to prevent or abort thrombus formation. To accomplish this shift, fibrinolyticaliy "enhanced" EC could be grown on synthetic vascular grafts, stents,26 artificial hearts, or indwelling catheters before implantation. All except the last of these devices has been the object of seeding studies in an effort to decrease thr~mbogenicity.".~~ Seeding with cells engineered For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From to produce supraphysiologic amounts of t-PA may contribute toward the accomplishment of this goal.
The success of protocols involving the implantation of EC genetically engineered to secrete t-PA (or any other therapeutic protein) will depend on the answers to several questions: Will high-level expression continue in vivo? Will the recombinant protein provoke an immune response (especially in the case of a human protein expressed in animals)? How long will the implanted cells survive once they are reimplanted? Will constitutive or induced levels of circulating PA1 be so high as to negate any effect of t-PA overproduction locally? Will unregulated local secretion of t-PA be harmful? Some of these questions have been addressed in other systems and it is clear that immunogenicity and long-term expression are major obstacle^.^'^^^ Nevertheless, studies by Wilson et aP9 and Nabel et ala indicate that it is possible to introduce genetically engineered cells into the vascular wall and for these cells to survive and retain expression of the lacZ gene for several weeks. It is now appropriate to determine whether the implantation of fibrinolytically "enhanced" EC will provide a therapeutic approach to intravascular thrombosis,
